calciol/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases malondialdehyde (circulating)
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Group 2 revealed a significant reduction in the serum levels of lipid profile measures, hs-CRP, alanine aminotransferase (ALT), STAT-3, NO, hepassocin, and MDA compared to the baseline and group 1 results.”
Quoted verbatim from A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.. - Study
- RCT
- Population
- NAFLD patients with type 2 diabetes on standard conventional therapy in both arms; cholecalciferol added in Group 2 vs placebo added in Group 1
A randomized placebo-controlled, double-blind study to investigate the effect of a high oral loading dose of cholecalciferol in non-alcoholic fatty liver disease patients, new insights on serum STAT-3 and hepassocin.2023PMID:37667938Permalink
Keep reading
- Everything the graph holds on calciol
- Every compound studied against Malondialdehyde (circulating)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M2RABQE2P0WMEWDD5CF60PB7